4//SEC Filing
NQ POF V GP, Ltd. 4
Accession 0001578563-22-000031
CIK 0000861838other
Filed
Oct 2, 8:00 PM ET
Accepted
Oct 3, 6:06 PM ET
Size
15.6 KB
Accession
0001578563-22-000031
Insider Transaction Report
Form 4
NQ POF V GP, Ltd.
DirectorOther
Transactions
- Other
Warrant
2022-09-28+14,115→ 14,115 totalExercise: $460.00From: 2022-09-28Exp: 2031-03-23→ Series Z Preferred Stock (14,115 underlying) - Other
Series X Preferred Stock
2022-09-28+5→ 5 total - Other
Warrant
2022-09-28+1,343,547→ 1,343,547 totalExercise: $0.46From: 2022-09-28Exp: 2031-03-23→ Common Stock (1,343,547 underlying) - Other
Series Z Preferred Stock
2022-09-28+14,115→ 14,115 total→ Common Stock (14,115 underlying)
NovaQuest Co-Investment Fund XV, L.P.
DirectorOther
Transactions
- Other
Warrant
2022-09-28+1,343,547→ 1,343,547 totalExercise: $0.46From: 2022-09-28Exp: 2031-03-23→ Common Stock (1,343,547 underlying) - Other
Warrant
2022-09-28+14,115→ 14,115 totalExercise: $460.00From: 2022-09-28Exp: 2031-03-23→ Series Z Preferred Stock (14,115 underlying) - Other
Series X Preferred Stock
2022-09-28+5→ 5 total - Other
Series Z Preferred Stock
2022-09-28+14,115→ 14,115 total→ Common Stock (14,115 underlying)
Footnotes (5)
- [F1]On September 28, 2022, Issuer completed its merger ("Merger") with Aceragen, Inc. ("Aceragen"), in accordance with the terms of that certain Agreement and Plan of Merger, dated September 28, 2022 (the "Merger Agreement"). In connection with the Merger, NovaQuest Co-Investment Fund XV, L.P. ("NovaQuest") received five shares of Issuer non-voting, non-convertible Series X Preferred Stock in exchange for five shares of Aceragen Series X Preferred Stock.
- [F2]NQ POF V GP, Ltd. ("NovaQuest GP") has the power to vote and dispose of any securities directly owned by NovaQuest. NovaQuest GP's investment committee makes voting and investment decisions regarding securities held by NovaQuest. NovaQuest GP disclaims beneficial ownership of any securities held by NovaQuest except to the extent of its pecuniary interest therein.
- [F3]Pursuant to the Merger Agreement, NovaQuest received a warrant to purchase (i) 1,343,547 shares of Issuer Common Stock and (ii) 14,115 shares of Issuer non-voting, convertible Series Z Preferred Stock, in exchange for a warrant to purchase 618,800 shares of Aceragen common stock.
- [F4]Represents Issuer Series Z Preferred Stock issuable upon the exercise of the warrant reported in (3) above.
- [F5]Contingent upon stockholder approval of the conversion of Issuer Series Z Preferred Stock into shares of Issuer Common Stock, each share of Issuer Series Z Preferred Stock is convertible into 1,000 shares of Issuer Common Stock, at any time at the option of the holder thereof, subject to certain limitations.
Documents
Issuer
IDERA PHARMACEUTICALS, INC.
CIK 0000861838
Entity typeother
IncorporatedCayman Islands
Related Parties
1- filerCIK 0001949220
Filing Metadata
- Form type
- 4
- Filed
- Oct 2, 8:00 PM ET
- Accepted
- Oct 3, 6:06 PM ET
- Size
- 15.6 KB